MPZL2

Across TCGA pan-cancer cohorts, MPZL2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MPZL2 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MPZL2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MPZL2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

PDAC, HNSC, and GBM are the cancer types where MPZL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.276	0.569	<.001	66	view →
HNSC	OS	Tertile	II,III,IV	0.925	0.784	.021	14	view →
GBM	OS	Median	All	0.165	0.740	.038	3	view →
CCRCC	DFS	Tertile	All	0.948	0.454	.026	2	view →
LSCC	DFS	Tertile	II,III,IV	0.389	1.000	.040	2	view →
LUAD	OS	Quartile	III,IV	0.821	0.468	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MPZL2–PDAC (DFS)

Open the PDAC breakdown →